StreetInsider.com News Articles

Lake Street Starts Viking Therapeutic (VKTX) at Buy

Thu, 28 May 2026 08:54:05 -0400

(Updated - May 28, 2026 8:54 AM EDT)

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $89.00.

The analyst comments "We initiate coverage of Viking with a Buy rating and $89 PT, driven by VK2735 in obesity (~$3B risk-adjusted 2040 sales). Phase 3 programs are underway with potential regulatory approval and launch in 2028. Maintenance dosing remains key for durable weight loss, and Viking will be reading out data for maintenance regimens in 4Q26. Even with a small penetration of the obesity market, VK2735 has blockbuster potential. Additional upside

Lake Street Starts Viking Therapeutic (VKTX) at Buy

Thu, 28 May 2026 08:54:05 -0400

(Updated - May 28, 2026 8:54 AM EDT)

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $89.00.

Truist Securities Assumes Viking Therapeutic (VKTX) at Buy

Wed, 27 May 2026 06:09:59 -0400

(Updated - May 27, 2026 6:09 AM EDT)

Truist Securities analyst Gregory Renza assumes coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $83.00.

The analyst comments "We assume coverage of VKTX with an unchanged Buy rating at an $83 PT (from $75). We view VKTX as a differentiated player in a heavily saturated & highly competitive obesity landscape, tackling two key challenges associated with contemporary and newer therapies: time to efficacy - reaching 14.7% in 13 wks, without plateau - and long-term adherence - leveraging both SC & oral formulations for continuity of care, versatile

Truist Securities Assumes Viking Therapeutic (VKTX) at Buy

Wed, 27 May 2026 06:09:59 -0400

(Updated - May 27, 2026 6:09 AM EDT)

Truist Securities analyst Gregory Renza assumes coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $83.00.

Form 8-K Viking Therapeutics, For: May 19

Tue, 26 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26550884.html

Form 8-K Viking Therapeutics, For: May 19

Tue, 26 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26550884.html

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 21 May 2026 07:05:00 -0400

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June.

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 21 May 2026 07:05:00 -0400

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 21 May 2026 07:05:00 -0400

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 21 May 2026 07:05:00 -0400

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities